Insightful Word
  • Investing
  • Stock
  • Economy
  • Politics
  • Investing
  • Stock
  • Economy
  • Politics
No Result
View All Result
Insightful Word
No Result
View All Result
Home Investing

Amgen’s weight-loss injection cuts up to 20% in a year

admin by admin
November 26, 2024
in Investing
0
Amgen’s weight-loss injection cuts up to 20% in a year
0
SHARES
2
VIEWS
Share on FacebookShare on Twitter

Amgen Inc (NASDAQ: AMGN) says patients on its weight-loss injection in a mid-stage trial weighed up to 20% less on average after a year.

The biopharmaceutical giant is convinced its treatment will help lower body weight even further upon continued consumption (beyond 52 weeks) as it did not observe a plateau in the Phase II study.

The company’s chief scientific officer touted MariTime’s “differentiated profile and strong reduction of HbA1C” in a press release today.

Amgen stock is still down about 7.0% in premarket on Tuesday.

Why is Amgen stock down today?

Amgen shares are in the red primarily because its mid-stage trial fell a bit short of expectations.  

Analysts had forecast MariTide to help lower weight by 20% “at least”. Some had even called for up to 25% reduction in body weight in 52-weeks.

Nonetheless, the multinational said it will use today’s data to design a late-stage trial of MariTide that is “already deep into planning.”

Amgen is fully committed to strengthening its footprint in weight loss drugs that experts believe could be generating about $150 billion in sales (globally) per year by the end of this decade.

Amgen stock is currently down about 20% versus its year-to-date high on September 20th.      

How does Amgen compare to Eli Lilly

Amgen’s weight-loss injection puts it in direct competition with the likes of Eli Lilly and Novo Nordisk that have so far been the most in focus for obesity treatments.

Some even expect LLY to become the world’s first non-tech $1.0 trillion company as Zepbound continues to boost its sales next year.

That drug helped patients shed over 22% of their body weight in 72 weeks in a late-stage trial.

Novo Nordisk’s Wegovy, in comparison, delivered a 15% decline in weight over 68 weeks.

But Amgen expects its MariTide to enable patients lose weight much faster and in fewer shots versus competing treatments.

Amgen shares pay a dividend yield of 3.06% at writing, which makes them all the more attractive for income investors.

Should you buy Amgen stock on the weakness?

The sell-off in Amgen stock today may be worth buying considering Cantor Fitzgerald analyst Olivia Brayer sees upside in it to $405.

Her price target indicates potential for close to a 50% upside from here.

Additionally, Amgen Inc improved its per-share earnings from $3.23 last year to a much better-than-expected $5.27 in its latest reported quarter as revenue climbed 23% year-on-year to $8.5 billion.

The Nasdaq listed firm improved its profit margin in the third quarter by a whopping 800 basis points to 33% as well. Robert A.

Bradway – the company’s chief executive officer told investors at the time:

We continue to invest heavily in our rapidly advancing pipeline, with a focus on delivering innovative therapies across our core therapeutic areas.

The post Amgen’s weight-loss injection cuts up to 20% in a year appeared first on Invezz

Previous Post

Walmart amends DEI policy: why it matters, and why are companies becoming less ‘woke’?

Next Post

Why does Elon Musk want to buy MSNBC? And can he pull it off?

admin

admin

Next Post
Why does Elon Musk want to buy MSNBC? And can he pull it off?

Why does Elon Musk want to buy MSNBC? And can he pull it off?

Trending News

Expectations for Lululemon’s China business “may be too high,” Morgan Stanley says

Expectations for Lululemon’s China business “may be too high,” Morgan Stanley says

October 1, 2024
Will TikTok actually be banned?

Will TikTok actually be banned?

January 25, 2025
Saudi Arabia stocks higher at close of trade; Tadawul All Share up 0.86%

Saudi Arabia stocks higher at close of trade; Tadawul All Share up 0.86%

December 1, 2024
Subscribe to Insightful Word


    Recent News

    ARB eyes recovery as Arbitrum taps agentic DeFi revolution with $1M grant

    ARB eyes recovery as Arbitrum taps agentic DeFi revolution with $1M grant

    June 5, 2025
    Ripple releases $2.18B in XRP, price dips 2%

    Ripple releases $2.18B in XRP, price dips 2%

    June 5, 2025
    Nintendo Switch 2 launch sees shortages as 2.2M vie for units in Japan

    Nintendo Switch 2 launch sees shortages as 2.2M vie for units in Japan

    June 5, 2025
    Why Bank of America sees 13% upside on Roblox (RBLX)

    Why Bank of America sees 13% upside on Roblox (RBLX)

    June 5, 2025

    Recent News

    ARB eyes recovery as Arbitrum taps agentic DeFi revolution with $1M grant

    ARB eyes recovery as Arbitrum taps agentic DeFi revolution with $1M grant

    June 5, 2025
    Ripple releases $2.18B in XRP, price dips 2%

    Ripple releases $2.18B in XRP, price dips 2%

    June 5, 2025

    Latest News

    • ARB eyes recovery as Arbitrum taps agentic DeFi revolution with $1M grant
    • Ripple releases $2.18B in XRP, price dips 2%
    • Nintendo Switch 2 launch sees shortages as 2.2M vie for units in Japan

    About Insightful Word

    • Contacts
    • Cookie Notice
    • Privacy Policy
    • Terms of Service
    • Trading tools
    • Contacts
    • Cookie Notice
    • Privacy Policy
    • Terms of Service
    • Trading tools

    Copyright © 2025 Insightfulword.com. All Rights Reserved.

    No Result
    View All Result
    • Investing
    • Stock
    • Economy
    • Politics

    Copyright © 2025 Insightfulword.com. All Rights Reserved.